Chai Discovery, the artificial intelligence company pioneering the prediction and reprogramming of biochemical molecule interactions, has announced a $130 million Series B funding round co-led by Oak HC/FT and General Catalyst. The investment values the company at $1.3 billion, underscoring growing confidence in its AI-driven approach to drug discovery. The funding follows a recent milestone in which Chai demonstrated that its latest generative AI models can design molecules with critical "developability" properties—such as solubility, stability, and metabolic profile—while also addressing previously intractable challenges in molecular design. This capability marks a significant leap forward in the field, as it enables the creation of drug candidates that are not only effective but also more likely to succeed in clinical development. Chai’s platform leverages deep learning to model complex molecular interactions at scale, allowing researchers to explore vast chemical spaces and identify novel compounds with precision. By integrating physical and biological constraints into its AI models, Chai reduces the time and cost traditionally associated with early-stage drug discovery. The company’s technology is already being applied across multiple therapeutic areas, with several programs in preclinical development. The new capital will be used to expand its AI infrastructure, grow its team of computational chemists and biologists, and advance its pipeline into clinical trials. Chai Discovery’s progress reflects a broader trend in biotech, where AI is transforming how molecules are discovered and optimized. With this latest round, the company is well-positioned to accelerate the development of next-generation therapeutics, particularly for diseases with limited treatment options.